General Rules for the Clinical and Pathological Study of Primary Liver Cancer, Nationwide Follow-Up Survey and Clinical Practice Guidelines: The Outstanding Achievements of the Liver Cancer Study Group of Japan

Kudo, Masatoshi; Kitano, Masayuki; Sakurai, Toshiharu; Nishida, Naoshi

doi:10.1159/000439101

Cited by 237 publications

(168 citation statements)

References 30 publications

Supporting

Mentioning

163

Contrasting

Order By: Relevance

“…According to the Child-Pugh classification, half of the patients were classified as class A, and the other half as class B. The tumor stages were classified as III ( n = 2) and IVA ( n = 4), according to the Liver Cancer Study Group of Japan[23]. …”

Section: Resultsmentioning

confidence: 99%

Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma

Saeki¹,

Yamamoto²,

Yamasaki³

et al. 2016

WJG

View full text Add to dashboard Cite

AIMTo evaluate the inhibitory effects of deferasirox (DFX) against hepatocellular carcinoma (HCC) through basic and clinical studies.METHODSIn the basic study, the effect of DFX was investigated in three hepatoma cell lines (HepG2, Hep3B, and Huh7), as well as in an N-nitrosodiethylamine-induced murine HCC model. In the clinical study, six advanced HCC patients refractory to chemotherapy were enrolled. The initial dose of DFX was 10 mg/kg per day and was increased by 10 mg/kg per day every week, until the maximum dose of 30 mg/kg per day. The duration of a single course of DFX therapy was 28 consecutive days. In the event of dose-limiting toxicity (according to the Common Terminology Criteria for Adverse Events v.4.0), DFX dose was reduced.RESULTSAdministration of DFX inhibited the proliferation of hepatoma cell lines and induced the activation of caspase-3 in a dose-dependent manner in vitro. In the murine model, DFX treatment significantly suppressed the development of liver tumors (P < 0.01), and significantly upregulated the mRNA expression levels of hepcidin (P < 0.05), transferrin receptor 1 (P < 0.05), and hypoxia inducible factor-1α (P < 0.05) in both tumor and non-tumor tissues, compared with control mice. In the clinical study, anorexia and elevated serum creatinine were observed in four and all six patients, respectively. However, reduction in DFX dose led to decrease in serum creatinine levels in all patients. After the first course of DFX, one patient discontinued the therapy. We assessed the tumor response in the remaining five patients; one patient exhibited stable disease, while four patients exhibited progressive disease. The one-year survival rate of the six patients was 17%.CONCLUSIONWe demonstrated that DFX inhibited HCC in the basic study, but not in the clinical study due to dose-limiting toxicities.

show abstract

Section: Resultsmentioning

confidence: 99%

Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma

Saeki¹,

Yamamoto²,

Yamasaki³

et al. 2016

WJG

View full text Add to dashboard Cite

show abstract

“…The diagnosis of HCC was based on imaging results and elevated serum levels of alpha-fetoprotein and/or des-gamma-carboxy prothrombin. We assessed HCC tumor stage using the criteria of the Liver Cancer Study Group of Japan, 6th edition [22]. Sorafenib was administered to patients with advanced HCC who were confirmed to be transcatheter arterial chemoembolization refractory, showed evidence of extrahepatic spread (EHS), and/or had macrovascular invasion.…”

Section: Methodsmentioning

confidence: 99%

No Muscle Depletion with High Visceral Fat as a Novel Beneficial Biomarker of Sorafenib for Hepatocellular Carcinoma

et al. 2018

View full text Add to dashboard Cite

Background: Sorafenib is a standard therapy for patients with advanced hepatocellular carcinoma (HCC). However, no predictive biomarkers of sorafenib efficacy have been discovered. Herein, we investigated the impact of body composition, such as skeletal muscle and visceral fat, on the prognosis of advanced HCC patients treated with sorafenib. Methods: We enrolled 100 patients with advanced HCC treated with sorafenib. Prior to receiving sorafenib therapy, skeletal muscle index (SMI) and visceral fat area (VFA) were measured using computed tomography at the third lumbar vertebra and umbilical level, respectively. Muscle depletion was defined as an SMI value < 42 cm²/m² in men and < 38 cm²/m² in women. High VFA (H-VFA) was defined as a value ≥100 cm². In addition to SMI and VFA, we also analyzed various clinical parameters as potential prognostic factors. Results: Multivariate analysis showed that having a tumor number < 7 (hazard ratio [HR] = 0.409, p < 0.001), absence of extrahepatic spread (EHS) (HR = 0.562, p < 0.001), absence of muscle depletion (HR = 0.498, p = 0.006), and H-VFA (HR = 0.556, p = 0.031) were significant factors for long-term survival. Therefore, we evaluated the prognosis of those with no muscle depletion with H-VFA. The no muscle depletion with H-VFA group showed significantly longer survival than the other group (median survival time 15.6 vs. 11.0 months, p = 0.003). Multivariate analysis showed that having a tumor number < 7 (HR = 0.454, p = 0.001), absence of EHS (HR = 0.511, p = 0.008), and no muscle depletion with H-VFA (HR = 0.454, p = 0.002) were significant predictors of survival. Conclusions: We identified no muscle depletion with H-VFA as a novel biomarker for advanced HCC patients treated with sorafenib.

show abstract

“…The histologic classification of tumors and the background liver was based on the system established by the Liver Cancer Study Group of Japan (20). The histologic differentiation of HCC (well, moderate, or poor) was determined according to the Edmondson grade (20,21).…”

Section: Surgical Procedures and Histopathological Assessmentsmentioning

confidence: 99%

“…The histologic differentiation of HCC (well, moderate, or poor) was determined according to the Edmondson grade (20,21). Both the fibrotic stage and the activity of hepatitis in the background liver were also recorded according to the classification proposed by Desmet et al (22).…”

Section: Surgical Procedures and Histopathological Assessmentsmentioning

confidence: 99%

Statin use is associated with a reduced risk of hepatocellular carcinoma recurrence after initial liver resection

Kawaguchi

Sakamoto

Ito

et al. 2017

BST

View full text Add to dashboard Cite

General Rules for the Clinical and Pathological Study of Primary Liver Cancer, Nationwide Follow-Up Survey and Clinical Practice Guidelines: The Outstanding Achievements of the Liver Cancer Study Group of Japan

Cited by 237 publications

References 30 publications

Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma

Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma

No Muscle Depletion with High Visceral Fat as a Novel Beneficial Biomarker of Sorafenib for Hepatocellular Carcinoma

Statin use is associated with a reduced risk of hepatocellular carcinoma recurrence after initial liver resection

Contact Info

Product

Resources

About